Management of low‐grade cervical abnormalities detected at screening: which method do women prefer?

Whynes, D. K.; Woolley, Claire; Philips, Z

doi:10.1111/j.1365-2303.2008.00565.x

Cited by 14 publications

(22 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another arguable choice seems the adoption of American utility scores in almost all the models that include CUAs, instead of scores based on validated European scales [52][53][54]. The rationale was not clarified, casting doubts on its appropriateness.…”

Section: Discussionmentioning

confidence: 99%

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

Koleva¹,

Compadri²,

Padula³

et al. 2011

Intern Emerg Med

View full text Add to dashboard Cite

The human papilloma virus (HPV) vaccine is a new and expensive vaccine potentially effective in the prevention of a cancer. We reviewed the economic evaluations (EEs) on the vaccine in the EU to assess their potential contribution to public decision-making in a fairly homogeneous setting where HPV vaccination has been widely adopted. A literature search on PubMed selected EEs on HPV vaccines in the EU for the period 2007-2010 using the terms "HPV vaccines" and "Costs and cost analysis." Fifteen articles were eventually selected. All studies were based on modelling techniques, either "cohort" or "dynamic transmission": three were cost utility, three cost-effectiveness, and the remainder included both. The ten studies explicitly assessing one of the two vaccines were all sponsored by their manufacturer, while the five studies unrelated to the vaccine type were funded by public agencies. Apart from two studies, utility estimates were always obtained from three US sources. Direct costs were always vaccination, diagnosis and treatment of related pathologies. Incremental cost-effectiveness ratio (ICER) results were less favourable when life years gained were valued rather than quality-adjusted life years, genital warts were excluded, and booster doses and extension of vaccination to men were included in the base-case analysis. All but one of the sponsored EEs recommend in favour of the vaccination strategy, which is dominant in one English study. The ICER results were very sensitive to discount rates, followed by duration of protection and vaccine price. At such an early stage, when the vaccines' efficacy have been demonstrated by well-designed studies, it is not possible (and not even reasonable) to wait for several years to measure their effectiveness; public decision-makers might benefit more from EEs designed to indicate sustainable prices using realistic estimates of crucial variables like coverage rates, rather than referring to a large number of assumptions in order to show acceptable cost-effectiveness.

show abstract

Section: Discussionmentioning

confidence: 99%

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

Koleva¹,

Compadri²,

Padula³

et al. 2011

Intern Emerg Med

View full text Add to dashboard Cite

show abstract

“…Further studies from the UK, evaluating women's overall preferences between cervical cancer screening strategies with comparatively higher sensitivity, at the cost of lower specificity, indicated an overall preference for comparative gains in sensitivity when traded with lower specificity. 86,87 While we have performed extensive one-way sensitivity analysis on the modelling results, we have not performed a probabilistic sensitivity analysis. The modelling exercise suggests, however, that the key area of uncertainty for drawing more affirmative conclusions on the true cost-effectiveness of automated compared with manual reading rests with the need for improved understanding and empirical research on the quality-of-life implications and women's preferences for trading for improvements in sensitivity.…”

Section: Economic Analysismentioning

confidence: 99%

MAVARIC – a comparison of automation-assisted and manual cervical screening: a randomised controlled trial

Kitchener

Blanks²,

Cubie³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. ii ii HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for resea...

show abstract

“…Both NG and FNA cytopathology research had comparable frequency and distribution of RCTs, SRs and MAs (table 1). Noncytopathologists performed most of the gynecology RCTs [8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43]. The noncytopathologists to cytopathologists ratio was 4.3:1.…”

Section: Resultsmentioning

confidence: 99%

Systematic Review, Meta-Analysis and Randomized Controlled Trials in Cytopathology

AbdullGaffar

2012

Acta Cytologica

View full text Add to dashboard Cite

Objectives: Evidence-based medicine (EBM) relies on systematic review (SR), meta-analysis (MA) and randomized controlled trials (RCTs). These EBM tools are more commonly used in clinical medicine than in laboratory medicine. The extent of their use in cytopathology is not clear. The purpose of this study was to investigate the frequency of SR, MA and RCTs in cytopathology compared to other laboratory and clinical medicine specialties. Study Design: A literature-based search for SRs, MAs and RCTs in cytopathology was performed. Several electronic databases were searched without date restrictions. Four journals in cytopathology, pathology and clinical medicine were also searched over 6 years. Results: Gynecology cytology utilized SRs, MAs and RCTs more frequently (83%) than nongynecology and fine needle aspiration cytology. Cytopathology, histopathology and laboratory medicine journals showed comparable rates of 0.5–1.1% in papers reporting SRs, MAs and RCTs. Specialty medical journals showed a higher rate of 5.6% and general medical journals showed a much higher rate of 30%. Conclusions: SR, MA and RCTs are less frequently utilized in pathology than in clinical medicine. Cytopathologists should be more aware of the benefits of SR and MA in resolving uncertainties and improving the clinical applicability of level III diagnostic studies.

show abstract

Management of low‐grade cervical abnormalities detected at screening: which method do women prefer?

Cited by 14 publications

References 26 publications

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

MAVARIC – a comparison of automation-assisted and manual cervical screening: a randomised controlled trial

Systematic Review, Meta-Analysis and Randomized Controlled Trials in Cytopathology

Contact Info

Product

Resources

About